In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS, enjoy another 80 days of free consultation

 

A gender perspective on incidence, management, short- and long term outcome of cardiogenic shock complicating ST-elevation myocardial infarction - A report from the SWEDEHEART register

Session Poster Session 2

Speaker Sofia Sederholm Lawesson

Congress : ESC Congress 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : ST-Elevation Myocardial Infarction (STEMI)
  • Session type : Poster Session
  • FP Number : P1726

Authors : S Sederholm Lawesson (Linkoping,SE), D Venetsanos (Stockholm and Linköping,SE), M Fredriksson (Linkoping,SE), T Jernberg (Stockholm,SE), N Johnston (Uppsala,SE), A Ravn-Fischer (Gothenburg,SE), J Alfredsson (Linkoping,SE)

Authors:
S Sederholm Lawesson1 , D Venetsanos2 , M Fredriksson3 , T Jernberg4 , N Johnston5 , A Ravn-Fischer6 , J Alfredsson1 , 1Linkoping University Hospital and Linkoping University , Department of Cardiology and Department of Medical and Health Sciences - Linkoping - Sweden , 2Karolinska University Hospital and Linköping University, Section of Cardiology, Huddinge and Department of Medical and Health Sciences, Linköping - Stockholm and Linköping - Sweden , 3Linkoping University, Occupational and Environmental Medicine, Department of Clinical and Experimental Medicine - Linkoping - Sweden , 4Danderyd University Hospital, Department of Clinical Sciences, Karolinska Institutet - Stockholm - Sweden , 5Uppsala University Hospital, Department of Medical Sciences, Cardiology - Uppsala - Sweden , 6Sahlgrenska University Hospital, Department of Molecular and Clinical Medicine, Institution of Medicine - Gothenburg - Sweden ,

Citation:

Background

Cardiogenic shock [CS] is a severe complication of ST-elevation myocardial infarction [STEMI]. An increased use of primary percutaneous coronary intervention [PPCI] has been associated with a decline in CS incidence, and a better prognosis. Female gender has been associated with a worse prognosis in STEMI, but whether there is a gender difference in incidence and outcome of CS complicating STEMI is not known.

Purpose

The objectives of this study were to compare the genders regarding incidence, management, and prognosis of CS complicating STEMI.

Methods

Patients with STEMI and CS were identified in SWEDEHEART 2005-2014. Cardiogenic shock was defined as any of; 1) systolic blood pressure [BP] <90 mm Hg =30 min, 2) signs of tissue hypoperfusion, 3) cardiac index <1,8 l/min/m2, 4) ionotropic drugs and/or need of intra-aortic balloon pump. Multiple logistic and cox regression analyses were done with reperfusion therapy, in-hospital and 1-year mortality as dependent variables.

Results

Among 56072 STEMI patients 3134 CS cases were identified. Women more often than men developed CS (6.3 vs 5.2%, p<0.001).  The age-adjusted incidence of CS did not change in women, whereas in men the incidence increased by 2.7% yearly. Women had a less chance of receiving reperfusion therapy, OR 0.77 (95% CI 0.65-0.92), but had neither higher in-hospital mortality (OR 1.01, 95% CI 0.85-1.19), nor higher 1-year mortality (OR 0.97, 95% CI 0.70-1.33). Upon age stratification the gender difference in reperfusion was only evident among the oldest (>80 years).

Conclusion

Women had higher risk of CS than men when stricken by STEMI, but whereas CS incidence increased in men it was stable in women. Although women had less likelihood of receiving reperfusion therapy, adjusted in-hospital, and 1-year mortality was without any gender difference. The rate of reperfusion was especially low in elderly women, where there seems to be room for improvement.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are